AVALIAÇÃO DA ATIVIDADE ANTI-HIPERTENSIVA DO EXTRATO DE Arrabidaea chica Verlot EM RATOS ESPONTANEAMENTE HIPERTENSOS

A espécie Arrabidaea chica Verlot (Bignoniaceae) é indicada para o tratamento de doenças de pele, cálculos renais, hipertensão arterial sistêmica, e no combate à anemia. Seu extrato etanólico foi quimicamente investigado e avaliado como fator no controle do tônus vascular e pressão arterial, utilizando-se como modelo anéis isolados da artéria mesentérica superior de ratos espontaneamente hipertensos (SHR). Este trabalho reporta o relaxamento concentração dependente da adição cumulativa do EAC no endotélio intacto ou sem endotélio, bem como a avaliação da influência do íon cálcio sobre a resposta do EAC. Os resultados em conjunto encontrados sugerem que o princípio ativo presente em Arrabidaea chica apresenta atividade sobre os mecanismos envolvidos na hipertensão arterial e que sua ação decorre do bloqueio dos canais de cálcio tipo L.Descritores: Arrabidaea. atividade anti hipertensiva.AbstractEvaluation of antihypertensive activity of Arrabidaea chica Verlot extract in rat SHR. The species Arrabidaea Verlot Chica (Bignoniaceae) is indicated for the treatment of skin diseases, kidney stones, high blood pressure, anti-inflammatory and anti-anemia. Its ethanol extract was chemically investigated and evaluated as a factor in the control of vascular tone and blood pressure, using as a model rings isolated superior mesenteric artery of spontaneously hypertensive rats (SHR). This work reports the relaxation concentration dependent and cumulative addition of the EAC in the intact endothelium or without endothelium, as well as evaluating the influence of calcium ions on the EAC’s response. The results found together, suggest that the active ingredient present in Arrabidaea chica shows activity on the mechanisms involved in hypertension and that his action stems from the blockade of L-type calcium channelsDescriptors: Arrabidaea. anti hypertensive activity

The state of health in the European Union (EU-27) in 2019: a systematic analysis for the Global Burden of Disease study 2019

Background: The European Union (EU) faces many health-related challenges. Burden of diseases information and the resulting trends over time are essential for health planning. This paper reports estimates of disease burden in the EU and individual 27 EU countries in 2019, and compares them with those in 2010.Methods: We used the Global Burden of Disease 2019 study estimates and 95% uncertainty intervals for the whole EU and each country to evaluate age-standardised death, years of life lost (YLLs), years lived with disability (YLDs) and disability-adjusted life years (DALYs) rates for Level 2 causes, as well as life expectancy and healthy life expectancy (HALE).Results:In 2019, the age-standardised death and DALY rates in the EU were 465.8 deaths and 20,251.0 DALYs per 100,000 inhabitants, respectively. Between 2010 and 2019, there were significant decreases in age-standardised death and YLL rates across EU countries. However, YLD rates remained mainly unchanged. The largest decreases in age-standardised DALY rates were observed for "HIV/AIDS and sexually transmitted diseases" and "transport injuries" (each -19%). "Diabetes and kidney diseases" showed a significant increase for age-standardised DALY rates across the EU (3.5%). In addition, "mental disorders" showed an increasing age-standardised YLL rate (14.5%).Conclusions: There was a clear trend towards improvement in the overall health status of the EU but with differences between countries. EU health policymakers need to address the burden of diseases, paying specific attention to causes such as mental disorders. There are many opportunities for mutual learning among otherwise similar countries with different patterns of disease

Pervasive gaps in Amazonian ecological research

Biodiversity loss is one of the main challenges of our time,1,2 and attempts to address it require a clear un derstanding of how ecological communities respond to environmental change across time and space.3,4 While the increasing availability of global databases on ecological communities has advanced our knowledge of biodiversity sensitivity to environmental changes,5–7 vast areas of the tropics remain understudied.8–11 In the American tropics, Amazonia stands out as the world’s most diverse rainforest and the primary source of Neotropical biodiversity,12 but it remains among the least known forests in America and is often underrepre sented in biodiversity databases.13–15 To worsen this situation, human-induced modifications16,17 may elim inate pieces of the Amazon’s biodiversity puzzle before we can use them to understand how ecological com munities are responding. To increase generalization and applicability of biodiversity knowledge,18,19 it is thus crucial to reduce biases in ecological research, particularly in regions projected to face the most pronounced environmental changes. We integrate ecological community metadata of 7,694 sampling sites for multiple or ganism groups in a machine learning model framework to map the research probability across the Brazilian Amazonia, while identifying the region’s vulnerability to environmental change. 15%–18% of the most ne glected areas in ecological research are expected to experience severe climate or land use changes by 2050. This means that unless we take immediate action, we will not be able to establish their current status, much less monitor how it is changing and what is being lostinfo:eu-repo/semantics/publishedVersio